Rtw Investments Reduces $71M in Cogent Biosciences, Inc. ($COGT)

RTW Investments cut its holdings in COGT by 28%, now holding 5.46 million shares.

Written by Trueearnings · Published Jun 13, 2026, 5:37 AM EDT

Key Points

RTW Investments reduced its stake in COGT by 2,133,566 shares, decreasing its position by 28% to 5,458,675 shares valued at $180.7 million.
COGT shares are trading around $33.10, with analysts maintaining a positive outlook and a target price as high as $67.
Insider buying on June 9, 2026, involved six individuals purchasing 17,901 shares each, while analysts continue to rate the stock positively.

RTW Investments recently filed a Form 13F with the SEC, revealing a significant reduction in its holdings of COGT. The fund cut its position by 2,133,566 shares, representing a 28% decrease. As of the reporting period, RTW holds 5,458,675 shares valued at approximately $180.7 million.

What Changed in RTW Investments' COGT Position

RTW Investments trimmed its position in COGT from 7,592,241 shares to 5,458,675 shares, a reduction of 2,133,566 shares or 28%. The remaining shares are valued at about $180.7 million, reflecting a notable decrease in the fund's commitment to COGT during the reporting period.

Other Institutional Activity in COGT

Other major institutional investors also made moves in COGT. FMR LLC increased its holdings by 35,781 shares, bringing its total to 23,122,748 shares worth roughly $889.9 million. BlackRock, Inc. significantly boosted its stake by 3,070,423 shares, ending with 16,045,014 shares valued at $617.6 million. Deerfield Management Company, L.P. maintained its position with 9,043,903 shares valued at $348.1 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC established new positions, holding 7,333,333 and 6,894,959 shares, valued at $282.3 million and $265.4 million, respectively. Janus Henderson Group PLC increased its stake by 1,427,717 shares, now holding 5,965,125 shares worth $229.6 million.

COGT Stock Snapshot

COGT shares are currently trading around $33.10. The stock's performance has been closely watched, with analysts maintaining a generally positive outlook. COGT's market movements are noteworthy given the recent institutional changes and the stock's potential for future growth.

Insider Buying and Selling at Cogent Biosciences, Inc.

On June 9, 2026, several insiders at COGT made significant purchases. Peter Evan Harwin, Todd Shegog, Karen Jean Ferrante, Christopher Cain, Matthew Ros, and Arlene Morris each bought 17,901 shares. These transactions were not part of a pre-planned trading program, indicating personal confidence in the company's prospects.

Analysts Set New Price Targets

Analysts have been active in updating their views on COGT. On May 6, 2026, HC Wainwright & Co. maintained its buy rating with a $55 price target. Jefferies assumed coverage with a buy rating and the same target on March 16, 2026. Piper Sandler also maintained a buy rating with a $52 target on February 18, 2026. The consensus among analysts is a buy recommendation, with a mean target price reflecting optimism about COGT's future performance.

About COGT

COGT operates in the biotechnology sector, focusing on developing innovative treatments for various diseases. The company is headquartered in the United States and is known for its commitment to advancing medical research and health solutions.

Bottom Line

RTW Investments' decision to reduce its stake in COGT by over 2.1 million shares is a significant move, reflecting a strategic adjustment in its portfolio. Investors track such changes for insights into fund managers' confidence in a company's future. It's important to remember that 13F filings are backward-looking and may not represent the current position of the investor. COGT continues to be a focus of institutional and analyst attention, with positive insider activity and analyst ratings supporting its potential growth trajectory.